Competition record
Thermo Fisher Scientific
Deep profile · 0 linked library matters
Thermo Fisher sells the instruments, the reagents those instruments consume, and the Fisher Scientific catalog labs order from. A validated assay on an installed machine is hard to move to Danaher, Agilent, or Sartorius.
Overview
Thermo Fisher is based in Waltham and combines analytical instruments, a vast catalog of reagents and lab plastics, the Patheon contract-manufacturing network, and the PPD clinical-research business. Pharmaceutical and academic labs are the customers.
Once a chromatography, mass-spectrometry, or PCR method is validated on a Thermo instrument, the quality system names that vendor's columns, vials, and reagents. Danaher, Agilent, Waters, and Sartorius sell alternative platforms, but switching means a revalidation, not a simple purchase order.
Patheon manufactures drug substance and fill-finish for biotech clients who do not own plants, so those clients depend on slot availability. The Fisher Scientific channel is how smaller labs buy everyone else's consumables as well, which gives Thermo a distribution role beyond its own instruments.
Competition footprint
Installed instruments pull a multi-year stream of proprietary reagents and service contracts.
Patheon capacity slots are scarce for biotechs that lack their own factories.
Catalog distribution gives Thermo a look at lab demand that pure instrument rivals do not have.
Consumer & business angle
A lab manager who changes instrument vendors must rewrite methods, retrain staff, and often refile a validation.
A small biotech waiting on a Patheon slot cannot start a trial on the date its protocol assumes.
What to watch
- Reagent and service attach rates on the installed base versus Danaher and Agilent displacements.
- Patheon capacity additions, and whether large pharma customers dual-source critical assays.
Markets
life science instruments · lab reagents · contract manufacturing
Also known as: thermo fisher, fisher scientific, patheon
Conduct themes
Linked cases in the library
No linked matters in the current library yet. The narrative above is still a market-power primer — check primary sources for live disputes.